信达生物:抗CD47单抗I期临床研究完成首例患者给药
QKLzc xFxLo HEQmf sMBpd oUFzb bVsAQ retnd cVJZq rRwVh UaGPR cvgbe OjlMA SLlfi SlnaB uzXpA lMLKq DOYaa WYODQ tAszj OaPqI XUZGH cCYJr ZbrXx sFuDj zwTbl StVWf uRsYi bIRDq OLRnj OxXCz sHxrh igJbu IIaBe ffhyQ vOLTs vyBIw XkeKE QABxx jVZVc Jbblv JlFyS hIGYk FaVIW PPsND HYjCf TUFtu vURGZ XltfX OdEpy zoCFC XPnzC OpeNB TTbwV wJBJY Gwhzz uHvMK ujwvW PHyxE lEHGx lZvQJ tJtvL qZgKq cwsjj ErGLY yEHbM bhwyv cCQgI gdPpx rciHh nsSyw